Vitamin D receptor activators

International Journal of Artificial Organs

Volumn 32, Issue 2, 2009, Pages 101-107

  Mazzaferro, Sandro ^a   Pasquali, Marzia ^a   Conte, Carmina ^a   Mandanici, Giusy ^a   Muci, Maria L ^a   Lavini, Raffaella ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hyperparathyroidism; PTH; Vitamin D

Indexed keywords

ACTIVE EVALUATION; HYPERPARATHYROIDISM; MEDICAL SPECIALTIES; PTH; RECEPTOR ACTIVATOR; VITAMIN D RECEPTOR; VITAMIN-D;

VITAMINS;

2 METHYLENE 19 NOR 1 ALPHA HYDROXYBISHOMOPREGNACALCIFEROL; 22 OXACALCITRIOL; CALCIPOTRIOL; CALCITRIOL; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; DOXERCALCIFEROL; ERGOCALCIFEROL; FALECALCITRIOL; PARICALCITOL; PLACEBO; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

BLOOD VESSEL CALCIFICATION; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STRUCTURE; HUMAN; NONHUMAN; REVIEW; SECONDARY HYPERPARATHYROIDISM; SURVIVAL RATE; UREMIA;

EID: 67649354437     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880903200207     Document Type: Review

References (54)

1. 3. Med J Osaka Univ 1985, 35: 51-4.
2. Reichrath J. Vitamin D and the skin: an ancient friend, revisited. Exp Dermatol 2007; 16: 618-25.
3. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006; 84: 694-7.
4. Slatopolsky E, Finch J, Ritter C, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995; 26: 852-60.
5. Holliday LS, Gluck SL, Slatopolsky E, Brown AJ. 1,25-Dihydroxy-19-nor-vitamin D(2), a vitamin D analog with reduced bone resorbing activity in vitro. J Am Soc Nephrol 2000; 11: 1857-64.
6. Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J. 19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-32.
7. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38 (Suppl 5): S45-50.
8. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Pari calcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483-90.
9. Martin KJ, González E, Lindberg JS, et al. Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study. Am J Kidney Dis 2001; 38 (Suppl 5): S57-63.
10. Mitsopoulos E, Zanos S, Ginikopoulou E, Kyriklidou P, Meimaridou D, Sakellariou G. Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 2006; 48: 114-21.
11. Drüeke TB, McCarron DA. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med 2003; 31; 349: 496-9.
12. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56.
13. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-25.
14. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-80.
15. Tentori F, Hunt WC, Stidley CA, et al. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006; 70: 1858-65.
16. Zhang Z, Sun Sun L, Wang Y, et al Renoprotective role of the vitamin D receptor on diabetic nephropathy. Kidney Int 2008; 73: 163-71.
17. Mizobuchi M, Morrissey J, Finch JL, et al Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-806.
18. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17: 3382-93.
19. Wu-Wong JR, Nakane M, Ma J, Ruan X, Kroeger PE. VDR mediated gene expression patterns in resting human coronary artery smooth muscle cells. J Cell Biochem 2007; 15; 100: 1395-405.
20. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM. Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 2007; 22: 860-6.
21. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 2007; 72: 709-15.
22. Lopez I, Mendoza FJ, Aguilera-Tejero E, et al. The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats. Kidney Int 2008; 73: 300-7.
23. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17 (Suppl 10): S10-9.
24. St-Arnaud R, Arabian A, Yu VW, Akhouayri O, Knutson JC, Strugnell SA. 1alpha,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism. J Endocrinol Invest 2008; 31: 711-7.
25. Sjöden G, Smith C, Lindgren U, DeLuca HF. 1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 1985; 178: 432-6.
26. Brown AJ, Finch JL, Lopez-Hilker S, et al. New active analogues of vitamin D with low calcemic activity. Kidney Int Suppl 1990; 29: S22-7.
27. Tan AU Jr, Levine BS, Mazess RB, et al. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-23.
28. Frazao JM, Chesney RW, Coburn JW. Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group. Nephrol Dial Transplant 1998; 13 (Suppl 3): S68-72.
29. Maung HM, Elangovan L, Frazão JM, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison. Am J Kidney Dis 2001; 37: 532-43.
30. Slatopolsky E, Cozzolino M, Finch JL. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats. Kidney Int 2002; 62: 1277-84.
31. Zisman AL, Ghantous W, Schinleber P, Roberts L, Sprague SM. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol 2005; 25: 591-5.
32. van Ginkel PR, Yang W, Marcet MM, et al. 1 alpha-Hydroxyvitamin D2 inhibits growth of human neuroblastoma. J Neurooncol 2007; 85: 255-62.
33. Grostern RJ, Bryar PJ, Zimbric ML, et al. Toxicity and doseresponse studies of 1alpha-hydroxyvitamin D2 in a retinoblastoma xenograft model. Arch Ophthalmol 2002; 120: 607-12.
34. Attia S, Eickhoff J, Wilding G, et al. Randomized, doubleblinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 2437-43.
35. Petrich A, Kahl B, Bailey H, Kim K, Turman N, Juckett M. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk Lymphoma 2008; 49: 57-61.
36. Brown AJ, Finch J, Grieff M, et al. The Mechanism for the Disparate Actions of calcitriol and 22-Oxacalcitriol in the Intestine. Endocrinology 1993; 133: 1158-64.
37. Kobayashi T, Tsugawa N, Okano T, et al. The Binding Properties, with Blood Proteins, and Tissue Distribution of 22-Oxa-1alfa,25-Dihydroxyvitamin D3, a Noncalcemic Analogue of 1alfa- Dihydroxyvitamin D3, in Rats. J Biochem 1994; 115: 373-80.
38. Takeyama K, Masuhiro Y, Fuse H, et al. Selective Interaction of Vitamin D Receptor with Transcriptional Coactivators by a Vitamin Analog. Mol Cell Biol 1999; 19: 1049-55.
39. Monier-Faugere MC, Geng Z, Friedler RM, et al. 22-Oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure. Kidney Int 1999; 55: 821-32.
40. Shiizaki K, Negi S, Hatamura I, et al. Biochemical and Cellular Effects of Direct Maxacalcitol Injection into Parathyroid Gland in Uremic Rats. J Am Soc Nephrol 2005; 16: 97-108.
41. Okuno S, Ishimura E, Kitatani K, et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003; 18: 2613-21.
42. Tominaga Y, Matsuoka S, Sato T, et al. Clinical Features and Hyperplastic Patterns of Parathyroid Glands in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism Refractory to Maxacalcitol Treatment and Required Parathyroidectomy. Ther Apher Dial 2007; 11: 266-73.
43. Barker JN, Ashton RE, Marks R, et al. Topical Maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999; 141: 274-8.
44. M. Komine, Y. Watabe, S. Shimaoka, et al. The action of a novel vitamin D3 analogue, OCT,on immunomodulatory function of keratinocytes and lymphocytes. Arch Dermatol Res 1999; 291: 500-6.
45. Nakagawa K, Sasaki Y, Kato S, Kubodera N, Okano T. 22-Oxa,1alfa,25-Dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005; 26: 1044-54.
46. Nakatsuka K, Imanishi Y, Morishima Y, et al. Biological potency of a fluorinated vitamin D analogue in yperparathyroidism. Bone Miner 1992; 16: 73-81.
47. Komuro S, Sato M, Kanamaru H. Disposition and metabolism of F6-1alpha,25(OH)2vitaminaD3 and 1alpha,25(OH)2vitaminD3 in the parathyroid glands of rats dosed with tritiumlabeled compounds. Drug Metab Dispos 2003; 31: 973-8.
48. Honda A, Nakashima N, Shida Y, Mori Y, Nagata A, Ishizuka S. Modification of 1alpha,25(OH)2vitaminD3 metabolism by introduction of26,26,26,27,27,27-hexafluoro atoms in human promyelocytic leukaemia (HL-60) cells: isolation and identification of a novel bioactive metabolite, 26, 26, 26, 27, 27, 27-hexafluoro-1,23(S), 25triihydroxyvitaminD3. Biochem J 1993; 295 (Pt 2): 509-16.
49. Tanaka Y, DeLuca HF, Kobayashi Y, Ikekawa N. 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitaminD3: a highly potent, long-lasting analogue of 1alpha,25(OH)2vitaminD3. Arch Biochem Biophys 1984; 229: 348-54.
50. Akiba T, Marumo F, Owada A. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1998; 32: 238-46.
51. Nishizawa Y, Morii H, Ogura Y, De Luca HF. Clinical trail fo 26,26,26,27,27,27-hexafluoro-1,25-dihydroxyvitaminD3 in uremic patients on hemodialysis: preliminary report. Contrib Nephrol 1991; 90: 196-203.
52. Slatopolsky E, Finch JL, Brown AJ, et al. Effect of 2-Methylene-19-nor-20(S)-1α-Hydroxy-Bis-homo-pregnacalciferol (2MbisP), an Analog of Vitamin D, on Secondary Hyperparathyroidism. J Bone Miner Res 2007; 22: 686-94.
53. Brown AJ, Slatopolsky E. Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med 2008; 29: 433-52.
54. Williams KB, DeLuca HF. 2-Methylene-19-nor-20(S)-1α-Hydroxy-Bis- homo-pregnacalciferol(2MbisP), does not stimulate intestinal phosphate absorption at levels previously shown to suppress parathyroid hormone. Steroids 2008; 73: 1277-84.